Trajan Scientific and Medical (Trajan) Chief Executive Officer Stephen Tomisich, delivered the opening plenary at AusMedtech 2016 in Adelaide from 10 - 11 May, discussing how to grow and sustain scientific and medical device companies.
Mr Tomisich's address covered three key pillars to Trajan's business sustainability; foundation, activity, and risk mitigation.
View the full plenary video below, or on Trajan's YouTube channel.
Media contact information
Tel: +44 (0) 1244 403 100
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.